Effect of levothyroxine plus liothyronine combination therapy on hypothyroid patients quality of life

BackgroundLiothyronine combination with Levothyroxine(T4-T3) has been tried to improve the quality of life among hypothyroid patients on levothyroxine immunotherapy and normal thyroxine stimulating hormone levels. However, the efficacy of such a combination is unknown. The current review aimed to assess the effects of T4-T3 combination therapy on quality of life.AimsThe current review aimed to compare levothyroxine mono-therapy versus T4-T3 combination therapy on quality of life among hypothyroid patients.Methods The Pub Med and Google Scholar databases were systematically searched for relevant articles. Articles published in the English language from the first available article up to March 2020 were approached. The terms hypothyroidism, levothyroxine, and liothyronine were used. Out of hundred and eight articles retrieved, only six fulfilled the inclusion and exclusion criteria.Results In majority of randomized control trials (4 out of 6 RCTs), T4/T3combination therapy fail to show superiority over the standard levothyroxine mono-therapy.ConclusionLevothyroxine remain the standard of care in hypothyroid patient

Oral semaglutide adequate glycaemia control with safe cardiovascular ‎profile

BackgroundType 2 diabetes is a chronic and progressive disease that ‎associated with series complication such as major adverse ‎cardiovascular events. Adequate glycaemic control proven ‎to reduce this risk. Orally administered semaglutide ‎promising medication in managing patient with type 2 ‎diabetes.‎AimsTo assess the cardiovascular safety and efficacy of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes.Methods Pub Med, ‎Google Scholar, and EBSCO ‎ databases were ‎systematically search for relevant articles. The terms‎ diabetes‎, Glucagon-like peptide, semaglutide‎ were used. Out of hundred twenty-two records, only ‎four fulfilled ‎the inclusion criteria.Results Four placebo-controlled studies with oral semaglutide ‎were included. Single study concern about the cardiovascular safety of oral semaglutide ‎and showed that, ‎compared with placebo, semaglutide ‎ was not associated ‎with increased in the cardiovascular events. On the other ‎hand, the remaining trials shown that, semaglutide ‎ can ‎effectively control the blood glucose as evident by ‎reduction in HA1c.ConclusionOral semaglutide can effectively and safely lower blood glucose without increase in the major adverse ‎cardiovascular events‎‎ (MACE).